Please login to the form below
aTyr appoints rare disease expert as president
Frederic Chereau has senior experience at Shire and Genzyme
US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.
Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company's cardiovascular business.
He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.
Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau's appointment will guide the company's “global outreach and strategic partnerships”.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
